title: A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin.
abstract: This study aimed to develop a guideline for therapeutic drug monitoring (TDM) of vancomycin. We adopted the new guideline definition from the Institute of Medicine (IOM), adhered closely to the six domains of the Appraisal of Guidelines for Research & Evaluation II (AGREE II), and made recommendations based on systematic reviews. We established a Guideline Steering Group and a Guideline Development Group, formulated 12 questions in the form of Population, Intervention, Comparison, Outcome (PICO) and completed a literature search. As far as we know, we will develop the first evidenced-based guideline for vancomycin TDM under the framework of the Grade of Recommendations Assessment, Development and Evaluation (GRADE).
authors.affiliation: Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
authors.forename: Zhi-Kang
authors.initials: ZK
authors.lastname: Ye
authors.affiliation: Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.|Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, 100191, China.
authors.forename: Ken
authors.initials: K
authors.lastname: Chen
authors.affiliation: Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Gansu, 730000, China.|Chinese GRADE Center, Gansu, 730000, China.
authors.forename: Yao-Long
authors.initials: YL
authors.lastname: Chen
authors.affiliation: Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China. zhaisuodi@163.com.
authors.forename: Suo-di
authors.initials: SD
authors.lastname: Zhai
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics; D002681:China; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D014640:Vancomycin / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin
keywords: Development and Evaluation; Grade of Recommendations Assessment; guideline; therapeutic drug monitoring; vancomycin